Antimicrobial Agents and Chemotherapy

Erratum: Host bioenergetic parameters reveal cytotoxicity of antituberculosis drugs undetected using conventional viability assays (Antimicrobial Agents and Chemotherapy (2021) 65:10 (e00932-21) DOI: 10.1128/AAC.00932-21).  65. 2021

Host bioenergetic parameters reveal cytotoxicity of antituberculosis drugs undetected using conventional viability assays.  65. 2021

Intracellular tenofovir and emtricitabine concentrations in younger and older women with HIV receiving tenofovir disoproxil fumarate/emtricitabine.  64. 2020

In vitro activities of eravacycline and other antimicrobial agents against human mycoplasmas and ureaplasmas.  64. 2020

Fosamprenavir with ritonavir pharmacokinetics during pregnancy.  64. 2020

Treatment-shortening effect of a novel regimen combining clofazimine and high-dose rifapentine in pathologically distinct mouse models of tuberculosis.  63. 2019

Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection.  63. 2019

Race/ethnicity and protease inhibitor use influence plasma tenofovir exposure in adults living with HIV-1 in AIDS Clinical Trials Group Study A5202.  63. 2019

Pharmacokinetics of dapivirine transfer into blood plasma, breast milk, and cervicovaginal fluid of lactating women using the dapivirine vaginal ring.  63. 2019

A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis.  63. 2019

Amphotericin B induction with voriconazole consolidation as salvage therapy for FKS-associated echinocandin resistance in Candida glabrata septic arthritis and osteomyelitis.  63. 2019

Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by neisseria gonorrhoeae.  62. 2018

In vitro activities of the benzoquinolizine fluoroquinolone levonadifloxacin (WCK 771) and other antimicrobial agents against mycoplasmas and ureaplasmas in humans, including isolates with defined resistance mechanisms.  62. 2018

Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis.  62. 2018

In vitro study of the susceptibility of clinical isolates of trichomonas vaginalis to metronidazole and secnidazole.  62. 2018

High prevalence of Pneumocystis jirovecii dihydropteroate synthase gene mutations in patients with a first episode of Pneumocystis pneumonia in Santiago, Chile, and clinical response to trimethoprim-sulfamethoxazole therapy.  61. 2017

In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China.  61. 2017

In vitro activities of gepotidacin (GSK2140944) and other antimicrobial agents against human mycoplasmas and ureaplasmas.  61. 2017

Susceptibility of Mycobacterium tuberculosis cytochrome bd oxidase mutants to compounds targeting the terminal respiratory oxidase, cytochrome c.  61. 2017

In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human mycoplasmas and ureaplasmas.  60:7502-7504. 2016

Emtricitabine-Triphosphate in dried blood spots as a marker of recent dosing.  60:6692-6697. 2016

8-Hydroxyquinolines are boosting agents of copper-related toxicity in Mycobacterium tuberculosis.  60:5765-5776. 2016

In vitro exposure to PC-1005 and cervicovaginal lavage fluid from women vaginally administered PC-1005 inhibits HIV-1 and HSV-2 infection in human cervical mucosa.  60:5459-5466. 2016

Disulfiram and copper ions kill Mycobacterium tuberculosis in a synergistic manner.  59:4835-4844. 2015

In Vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas.  59:3627-3629. 2015

The mycobacterium tuberculosis outer membrane channel protein CpnT confers susceptibility to toxic molecules.  59:2328-2336. 2015

Analysis of Neisseria gonorrhoeae azithromycin susceptibility in the united states by the gonococcal isolate surveillance project, 2005 to 2013.  59:998-1003. 2015

Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.  59:570-578. 2015

Bacillus anthracis GrlA^V96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge.  58:7182-7187. 2014

Microbicidal power of alpha radiation in sterilizing germinating Bacillus anthracis spores.  58:1813-1815. 2014

Copper complexation screen reveals compounds with potent antibiotic properties against methicillin-resistant Staphylococcus aureus.  58:3727-3736. 2014

Pharmacokinetic and safety analyses of tenofovir and tenofovir- emtricitabine vaginal tablets in pigtailed macaques.  58:2665-2674. 2014

Randomized, double-blind, multicenter safety and efficacy study of rifalazil compared with azithromycin for treatment of uncomplicated genital Chlamydia trachomatis infection in women.  58:4014-4019. 2014

IreB, a Ser/Thr kinase substrate, influences antimicrobial resistance in Enterococcus faecalis.  57:6179-6186. 2013

Association of higher plasma vitamin d binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: Cause of a functional Vitamin D deficiency?.  57:5619-5628. 2013

Azithromycin to prevent bronchopulmonary dysplasia in Ureaplasma-infected preterm infants: Pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.  57:2127-2133. 2013

Real-time treatment guidelines: Considerations during the Exserohilum rostratum outbreak in the United States.  57:1573-1576. 2013

Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant staphylococcus aureus.  57:1447-1454. 2013

Copper-boosting compounds: A novel concept for antimycobacterial drug discovery.  57:1089-1091. 2013

Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.  56:5938-5945. 2012

Use of xylitol to enhance the therapeutic efficacy of polymethylmethacrylate-based antibiotic therapy in treatment of chronic osteomyelitis.  56:5839-5844. 2012

Nevirapine exposure with WHO pediatric weight band dosing: Enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.  56:5374-5380. 2012

Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.  56:3133-3137. 2012

Chromosomal mutations responsible for fluoroquinolone resistance in Ureaplasma species in the United States.  56:2780-2783. 2012

Oseltamivir inhibits H7 influenza virus replication in mice inoculated by the ocular route.  56:1616-1618. 2012

Identification of protein-protein interaction inhibitors targeting vaccinia virus processivity factor for development of antiviral agents.  55:5054-5062. 2011

Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.  55:4290-4294. 2011

In Vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the transplant-associated infection surveillance network.  55:3944-3946. 2011

A new small molecule specifically inhibits the cariogenic bacterium Streptococcus mutans in multispecies biofilms.  55:2679-2687. 2011

Decrease in penicillin susceptibility due to heat shock protein ClpL in Streptococcus pneumoniae.  55:2714-2728. 2011

Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.  55:1106-1113. 2011

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.  54:4137-4142. 2010

Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas.  54:2437-2447. 2010

Penicillin sulfone inhibitors of class D β-lactamases.  54:1414-1424. 2010

Evaluation of vancomycin and daptomycin potency trends (MIC Creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006 (Antimicrobial Agents and Chemotherapy (2009) 53, 10, (4127-4132)).  54:1383. 2010

Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.  54:707-717. 2010

Inhibition of herpesvirus replication by 5-substituted 4′- thiopyrimidine nucleosides.  53:5251-5258. 2009

Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006.  53:4127-4132. 2009

Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.  53:2139-2141. 2009

Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.  53:2189-2191. 2009

Activities of certain 5-substituted 4′-thiopyrimidine nucleosides against orthopoxvirus infections.  53:572-579. 2009

Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.  53:4015-4018. 2009

Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.  52:3776-3778. 2008

Association of fluconazole pharmacodynamics with mortality in patients with candidemia.  52:3022-3028. 2008

Role of porins for uptake of antibiotics by Mycobacterium smegmatis.  52:3127-3134. 2008

Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis.  52:2503-2511. 2008

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.  52:631-637. 2008

Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.  51:4297-4302. 2007

Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.  51:3104-3110. 2007

Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.  51:2208-2210. 2007

Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.  51:1795-1803. 2007

EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.  51:1055-1063. 2007

Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.  51:783-786. 2007

Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole.  50:4209-4210. 2006

Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.  50:3479-3484. 2006

Enteroviral meningitis: Natural history and outcome of pleconaril therapy.  50:2409-2414. 2006

Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis.  50:1982-1988. 2006

New Mycobactenum avium antifolate shows synergistic effect when used in combination with dihydropteroate synthase inhibitors.  49:4801-4803. 2005

Analysis of human immunodeficiency virus type 1 reverse transcriptase subunit structure/function in the context of infectious virions and human target cells.  49:3762-3769. 2005

Lipophilic antifolate trimetrexate is a potent inhibitor of trypanosoma cruzi: Prospect for chemotherapy of chagas' disease.  49:3234-3238. 2005

Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.  49:2541-2542. 2005

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.  49:2294-2301. 2005

Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.  49:952-958. 2005

Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis.  48:4163-4170. 2004

Insufficient evidence that extended-spectrum cephalosporins effectively prevent metastatic infections related to Klebsiella pneumoniae-caused liver abscess..  48:3640. 2004

SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.  48:3556-3558. 2004

Bis-Anthracycline Antibiotics Inhibit Human Immunodeficiency Virus Type 1 Transcription.  48:1652-1663. 2004

Orally Active Fusion Inhibitor of Respiratory Syncytial Virus.  48:413-422. 2004

Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women?.  48:430-436. 2004

Comparative In Vitro Susceptibilities and Bactericidal Activities of Investigational Fluoroquinolone ABT-492 and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.  47:3973-3975. 2003

Genotypes of Pneumocystis jiroveci Isolates Obtained in Harare, Zimbabwe, and London, United Kingdom.  47:3979-3981. 2003

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.  47:3149-3154. 2003

Uptake of nitrobenzylthioinosine and purine β-L-nucleosides by intracellular Toxoplasma gondii.  47:3247-3251. 2003

Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.  47:2685-2687. 2003

Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp..  47:636-642. 2003

Prevalence of plasmid-mediated quinolone resistance.  47:559-562. 2003

In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.  47:39-42. 2003

In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.  47:161-165. 2003

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.  46:1896-1905. 2002

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study.  45:3487-3496. 2001

Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.  45:3065-3069. 2001

Acyclovir for treatment of postherpetic neuralgia: Efficacy and pharmacokinetics.  45:2771-2774. 2001

Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.  45:2126-2128. 2001

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.  45:236-242. 2001

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.  44:2672-2678. 2000

Intracellular metabolism of β-L-2',3'-dideoxyadenosine: Relevance to its limited antiviral activity.  44:853-858. 2000

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.  44:688-692. 2000

Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells.  44:496-503. 2000

Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase.  44:2784-2793. 2000

Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model.  43:2389-2394. 1999

In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.  43:2571-2573. 1999

Metabolism and selective toxicity of 6-nitrobenzylthioinosine in Toxoplasma gondii.  43:2437-2443. 1999

Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group..  42:1139-1145. 1998

Bactericidal activities of ceftizoxime and cefotaxime against Streptococcus pneumoniae [3] (multiple letters).  42:1869-1870. 1998

In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex.  42:3315-3316. 1998

Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.  42:2989-2995. 1998

Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: Results from a randomized, controlled clinical trial.  42:1139-1145. 1998

Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.  41:881-885. 1997

Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men.  41:1843-1845. 1997

Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group..  40:2202-2205. 1996

Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains.  40:2775-2780. 1996

Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea.  40:1720-1721. 1996

Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.  40:2721-2726. 1996

Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections.  40:2202-2205. 1996

Structure-activity relationships of quinolone agents against Mycobacteria: Effect of structural modifications at the 8 position.  40:2363-2368. 1996

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.  39:1704-1710. 1995

Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: Identification of a novel inhibitor of influenza virus.  39:2204-2209. 1995

Mutacin II, a bactericidal lantibiotic from Streptococcus mutans.  39:2656-2660. 1995

Trends in susceptibility of Neisseria gonorrhoeae to ceftriaxone from 1985 through 1991.  39:917-920. 1995

Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene.  38:648-652. 1994

Decreased susceptibility to penicillin G and tet M plasmids in genital and anorectal isolates of Neisseria meningitidis.  38:1661-1663. 1994

Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate β enantiomers of cytidine analogs.  38:2300-2305. 1994

Comparison of ciprofloxacin and ceftriaxone as single-dose therapy for uncomplicated gonorrhea in women.  37:1670-1673. 1993

Cocaine hydrochloride and benzoylecgonine have no in vitro inhibitory effect against Neisseria gonorrhoeae.  35:1228-1229. 1991

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.  35:1181-1185. 1991

Comparison of cilofungin and amphotericin B for therapy of murine candidiasis.  34:1619-1621. 1990

INVITRO SUSCEPTIBILITY OF MUTANS STREPTOCOCCI TO ANTIMICROBIAL SUBSTANCES AS DETERMINED BY A MEMBRANE TRANSFER ASSAY.  34:153-155. 1990

In vitro susceptibility of mutans streptococci to antimicrobial substances as determined by a membrane transfer assay..  34:153-155. 1990

Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection.  33:167-170. 1989

Prevention for tubercidin host toxicity by nitrobenzylthioinosine 5'-monophosphate for the treatment of schistosomiasis.  33:824-827. 1989

Azole antifungal agents: Emphasis on new triazoles.  32:1-8. 1988

In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.  32:1500-1502. 1988

Treatment of uncomplicated gonorrhea with single-dose imipenem-cilastatin.  32:773-774. 1988

In vitro susceptibilities of suspected periodontopathic anaerobes as determined by membrane transfer assay.  31:1989-1993. 1987

Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers.  31:1317-1322. 1987

Pharmacology and toxicity of high-dose ketoconazole.  31:1874-1878. 1987

Comparative study of cefoperazone and spectinomycin for treatment of uncomplicated gonorrhea in men.  30:619-621. 1986

Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men.  30:267-269. 1986

Dose ranging study of cefpimizole (U-63196E) for treatment of uncomplicated gonorrhea in men.  29:849-851. 1986

In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.  30:25-30. 1986

Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84..  27:309-313. 1985

High-pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabinosyladenine, and arabinosylhypoxanthine in plasma and urine.  28:265-273. 1985

Evaluation of lithium as an inhibitory agent of herpes simplex virus in cell cultures and during reactivation of latent infection in rabbits..  25:522-523. 1984

Interaction of cefotaxime and aminoglycosides against enterococci in vitro.  24:847-850. 1983

Ceftriaxone: In vitro studies and clinical evaluation.  22:1-9. 1982

Clinical evaluation of moxalactam.  20:88-97. 1981

In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp..  19:114-116. 1981

Pharmacology, tolerance, and antiviral activity of vidarabine monophosphate in humans.  18:709-715. 1980

Clinical and laboratory evaluation of cefamandole in the therapy of Haemophilus spp. bronchopulmonary infections.  15:807-812. 1979

Correlation of aminoglycoside dosages with serum concentrations during therapy of serious gram-negative bacillary disease.  16:353-361. 1979

In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli.  16:864-868. 1979

In vitro activity of gentamicin, amikacin, and netilmicin alone and in combination with carbenicillin against Serratia marcescens.  10:878-884. 1976

Antimicrobial therapy of experimental enterococcal endocarditis.  8:564-570. 1975

Characterization and extrachromosomal control of bacteriocin production in Staphylococcus aureus..  4:49-57. 1973

Double-blind comparison of carbenicillin indanyl sodium, ampicillin, and cephalexin in treatment of urinary tract infection..  4:593-596. 1973

Mode of action of a Staphylococcus epidermidis bacteriocin..  2:456-463. 1972

Therapeutic program for Candida infection..  10:286-290. 1970